Sage Journals: Discover world-class research

Abstract

Objectives: Yokukansan (YKS) is a traditional Japanese Kampo medicine approved by the Ministry of Health, Labour and Welfare of Japan. Recently, in addition to its indications as a drug treatment, YKS has been shown to have ameliorative effects on various psychological and behavioral responses such as anxiety, aggression, and stress responses. Stress exposure activates not only the hypothalamic–pituitary–adrenal axis but also the sympathetic nervous system. Sympathetic activation in brain regions such as the paraventricular hypothalamic nucleus (PVN) stimulates elevation of plasma catecholamine (noradrenaline and adrenaline) levels. We previously reported that various stress-related neuropeptides and several kinds of stressors, such as restraint stress (RS), increase plasma catecholamine and that brain prostanoids and their synthases mediate these responses in rats. In the present study, to determine if YKS treatment can affect stress-induced sympathetic activation, we examined the effects of YKS treatment on the RS-induced elevation of plasma catecholamine levels and related prostanoid production in the PVN of rats. Methods: YKS (1000 mg/10 mL/kg, p.o.) or vehicle was administered to rats daily for 14 days, and all rats were exposed to RS for 60 min on day 14. Before and during stress exposure on day 14, blood samples and PVN dialysates were collected and analyzed by high-performance liquid chromatography and liquid chromatography-ion trap tandem mass spectrometry, respectively. Results: Our results showed that repeated administration of YKS suppressed the RS-induced increase in plasma adrenaline but not noradrenaline. Furthermore, YKS administration also suppressed the RS-induced elevation of both prostaglandin E2 and thromboxane B2 levels in the PVN. In addition, we found that repeated administration of YKS suppressed the RS-induced increase in serotonin, gamma-aminobutyric acid, and acetylcholine in the PVN. Conclusion: Our results suggest that YKS can ameliorate stress-induced sympathetic activation via inhibition of stress responses in the brain.

Keywords

paraventricular hypothalamic nucleus plasma catecholamines prostanoid stress sympathetic activation

Introduction

Stress exposure activates not only the hypothalamic–pituitary–adrenal (HPA) axis but also the sympathetic nervous system.^1,2 Sympathetic activation triggered in the brain regions such as the paraventricular hypothalamic nucleus (PVN) stimulates peripheral release and/or secretion of noradrenaline and adrenaline.^3,4 These peripheral catecholamines elicit systemic and/or local responses in their target organs, resulting in various sympathetic responses including elevation of blood pressure and heart rate. We previously reported that various stress-related neuropeptides such as corticotropin-releasing factor (CRF) and vasopressin^5,6 as well as several kinds of stressors, such as restraint stress (RS) and glucoprivation stress,^7–9 increase plasma catecholamine levels, and that prostanoids and their synthases in the brain mediate these responses in rats.

Yokukansan (YKS) is a traditional Japanese Kampo medicine approved by the Ministry of Health, Labour and Welfare of Japan, and has indications for neurosis, insomnia, night crying, and irritability in children.¹⁰ YKS is composed of 7 kinds of medicinal herbs, namely, Atractylodes Lancea (rhizome of Atractylodes japonica Koidz. ex Kitam., Compositae, 4.0 g), Poria (strain of Pinus densiflora Siebold and Zucc., Polyporaceae, 4.0 g), Cnidium Rhizome (rhizome of Cnidium officinale Makino, Umbelliferae, 3.0 g), Uncaria Thorn (hook-bearing stems of Uncaria rhynchophylla (Miq.) Miq., Rubiaceae, 3.0 g), Japanese Angelica (root of Angelica acutiloba (Siebold and Zucc.) Kitag., Umbelliferae, 3.0 g), Bupleurum (root of Bupleurum falcatum L., Umbelliferae, 2.0 g), and Glycyrrhiza (root of Glycyrrhiza uralensis Fisch., Laguminosae, 1.5 g), and was kindly provided by Tsumura & Co. (Tokyo, Japan) (http: www.worldfloraonline.org). Additionally, clinical studies have recently reported that YKS is also effective, without serious side effects, against the behavioral and psychological symptoms of dementia (BPSD), such as aggression and hallucinations, in patients with Alzheimer's disease^11–13 and other diseases or symptoms including borderline personality disorder and preoperative anxiety (see review by Mizoguchi and Ikarashi¹⁴). Similar to these clinical studies, such ameliorative effects of YKS have been reported in rodents that show BPSD-like behaviors. YKS improved aggression in various animal models such as amyloid precursor protein (APP) transgenic mice,¹⁵ thiamine-deficient rats,¹⁶ and rats with cholinergic degeneration in the nucleus basalis of Meynert,¹⁷ and anxiety-like behaviors in APP transgenic mice.¹⁵ These findings from clinical and experimental animal studies suggest that YKS has therapeutic effects on psychological/psychiatric symptoms.

In addition to the effects on BPSD-like symptoms, YKS seems to be involved in regulation of stress responses. It is well-known that corticosterone levels, which are the main indicator of HPA responses to stress in rodents, are elevated in response to various stressors. The effects of YKS on stress-induced corticosterone levels vary considerably, ranging from no effects^18–20 to suppressive effects.^21–23 This discrepancy is thought to be due, in part, to differences in the type and strength of stressors and the doses of YKS administered. YKS treatment also seems to affect stress responses other than corticosterone responses. In the brain, YKS administration decreases RS-induced Fos expression in the amygdaloid nuclei and prelimbic cortex, but not in the PVN, although neither single nor repeated administration of YKS had an effect on the basal or stressed levels of corticosterone.¹⁸ In contrast, in the PVN, YKS administration was shown to normalize stress-induced reductions in glucocorticoid receptor protein levels by regulating microRNA-18 expression.²³ Furthermore, YKS is known to ameliorate stress-induced behavioral abnormalities. Many previous studies reported that repeated administration of YKS ameliorated stress-induced behavioral changes such as anxiety-like behaviors, aggressive behaviors, and decreased social behaviors.^18,20,24,25 These findings suggested that oral administration of YKS affects central regulation of stress-induced behavioral responses. However, it remained unclear as to whether YKS can affect sympathetic responses to stress exposure or not.

YKS has been shown to affect neurotransmitter systems, including the serotonergic (5-HTergic), glutamatergic, and GABAergic systems.^26–28 Moreover, several studies demonstrated that the ameliorative effects of YKS on behavioral abnormalities are blocked by intraperitoneal administration of antagonists for the 5-hydroxy tryptamine (5-HT_1A), gamma-aminobutyric acid (GABA_A), or N-methyl-D-aspartate (NMDA) receptors in rats and mice.^{20,24,26,29,30} Although the underlying detailed mechanisms remain unclear, accumulating evidence raises the possibility that YKS acts directly or indirectly in the brain. It has been shown that YKS affects neurotransmitter levels in the brain, specifically, 5-HT in the prefrontal cortex³¹ and the hypothalamus,²⁶ acetylcholine (ACh) in the hippocampus,^27,32 and glutamate and GABA in whole brain homogenates.²⁸ However, it is unknown at present whether neurotransmitter levels are modulated by YKS treatment in the PVN, the major integrative center for sympathetic function and stress responses in the brain.²

In this study, we focused on the potential for YKS treatment to affect RS-induced elevation of plasma catecholamine (noradrenaline and adrenaline) levels and related prostanoid (prostaglandin [PG] E₂ and thromboxane [Tx] B₂) production in the rat PVN (Figure 1). In addition, we measured neurotransmitter levels in the PVN during stress exposure under YKS treatment.

Figure 1.

Experimental schedule. Arrows indicate daily administration of Yokukansan (YKS). On day 14, YKS was administered 4 h prior to the start of the dialysis experiment. Gray squares above the line on day 14 show the dialysate collection every 20 min.

Results

Effects of a Single Administration of YKS on RS-Induced Elevation of Plasma Catecholamine Levels

Exposure to RS for 60 min significantly increased plasma levels of noradrenaline and adrenaline (Figure 2). One-way ANOVA indicated that a single administration of YKS 4 h prior to RS exposure did not affect the stress-induced elevation of plasma noradrenaline or adrenaline levels (Figure 2).

Figure 2.

Effects of a single administration of YKS on the RS-induced elevation of plasma catecholamine levels. YKS was administered 4 h prior to the start of RS exposure. Plasma catecholamine levels after RS exposure for 60 min were measured. *Significantly different (P < .05) from the vehicle (V) + RS (−) group.

Effects of Repeated Administration of YKS on Body Weight

In our main experiment, YKS was administered for 14 days. Body weight was measured daily, just before YKS administration. Repeated administration of YKS for 14 days had no significant effect on body weight (Figure 3). On day 14, mean body weight was 355 ± 6.6 g for the vehicle + RS group (n = 12), and 352 ± 6.1 g for the YKS + RS group (n = 16).

Figure 3.

Effects of repeated Yokukansan (YKS) administration on body weight. Body weight was measured just before YKS administration for determination of dosage every day for 14 days.

Effects of Repeated Administration of YKS on RS-Induced Elevation of Plasma Catecholamine Levels

Two-way analysis of variance (ANOVA) indicated a significant main effect for time [F(3, 68) = 25.028, P < .01] on plasma noradrenaline levels, but no significant main effect for treatment or interaction between treatment and time (Figure 4). Plasma noradrenaline levels were increased during stress exposure compared to basal levels in both vehicle-treated and YKS-treated rats, and YKS did not affect the elevation of plasma noradrenaline. In contrast, there were significant main effects for treatment [F(1, 68) = 6.836, P < .05] and time [F(3, 68) = 30.241, P < .01] on plasma adrenaline levels and a significant interaction between treatment and time [F(3, 68) = 2.782, P < .05; Figure 4]. RS increased plasma adrenaline levels in both vehicle-treated and YKS-treated rats at 20 and 40 min. Furthermore, post-hoc analysis revealed that plasma adrenaline levels in YKS-treated rats were significantly suppressed compared with those of vehicle-treated rats after 60 min of RS, and the levels at 60 min showed no significant difference compared with the basal levels in YKS-treated rats.

Figure 4.

Effects of repeated YKS administration on the RS-induced elevation of plasma catecholamine levels. After administration of YKS for 14 days, plasma samples were collected during a 60-minute RS exposure on day 14. ○, vehicle + RS (n = 9); ●, YKS + RS (n = 10). *Significantly different (P < .05) from 0 min in each group; #significantly different (P < .05) from the vehicle + RS group.

The actual values for noradrenaline and adrenaline at 0 min were 73.9 ± 41.1 and 35.5 ± 14.5 pg/mL for the vehicle + RS group (n = 9), and 99.2 ± 31.6 and 92.7 ± 38.6 pg/mL for the YKS + RS group (n = 10), respectively.

Effects of Repeated YKS Administration on RS-Induced Elevation of PGE₂ and TxB₂ Levels in the PVN

There were significant main effects for treatment [F(1, 48) = 8.699, P < .01] and time [F(3, 48) = 3.244, P < .05] on the levels of PGE₂ in the PVN, but no significant interaction was found between them (Figure 5).³³ In vehicle-treated rats, the PGE₂ levels in the PVN were significantly increased at 40 min of RS (Figure 5; 156.8% of the basal level). In contrast, PGE₂ levels did not change during stress exposure in YKS-treated rats, and YKS significantly suppressed PGE₂ levels at 40 min compared with vehicle-treated rats.

Figure 5.

Effects of repeated YKS administration on the RS-induced elevation of PGE₂ and TxB₂ levels in the PVN. (A) After administration of YKS for 14 days, PVN dialysates were collected during a 60-minute RS exposure on day 14. ○, vehicle + RS (n = 6); ●, YKS + RS (n = 8). *Significantly different (P < .05) from 0 min in each group; #significantly different (P < .05) from the vehicle + RS group. (B) Diagrammatic representation of rat brain frontal plates from Paxinos and Watson,³³ showing the placement of the microdialysis probe. (C) Representative ion chromatograms for standard prostanoids and their internal standards from LC-ITMSⁿ analysis.

Two-way ANOVA indicated a significant main effect for treatment [F(1, 48) = 7.930, P < .01], but no significant main effect for time nor an interaction between treatment and time on TxB₂ levels in the PVN (Figure 5). Similar to PGE₂, TxB₂ levels in the PVN were significantly increased at 40 min (173.7% of the basal level) in vehicle-treated rats. In YKS-treated rats, TxB₂ levels showed no significant change during exposure to RS.

Effects of Repeated YKS Administration on Neurotransmitter Levels in the PVN

The 4 neurotransmitters measured in the dialysis experiments (5-HT, GABA, ACh, and histamine) showed different responses to 60 min of RS exposure in this study (Figure 6).³³ In the PVN dialysate, two-way ANOVA indicated a significant main effect of treatment for both 5-HT and GABA [5-HT: F(1, 28) = 18.460, P < 0.01; GABA: F(1, 28) = 18.240, P < .01], but no significant main effect for time nor interaction between treatment and time. In vehicle-treated rats, RS significantly increased 5-HT levels at 20 and 40 min and GABA levels at 60 min (Figure 6). In contrast, neither 5-HT nor GABA levels changed during the 60-min stress exposure in YKS-treated rats. Post-hoc analysis revealed that the RS-induced increase in 5-HT (at 20 and 40 min) and GABA (at 60 min) levels were suppressed by YKS treatment. Moreover, there were significant main effects of treatment [F(1, 28) = 16.362, P < .01] and time [F(3, 28) = 4.515, P < .05] on ACh levels and also a significant interaction between treatment and time [F(3, 28) = 4.768, P < .01]. In the PVN, ACh levels significantly increased at 40 min (Figure 6), and this increase was suppressed to basal levels. No significant main effects on histamine levels or interactions were found.

Figure 6.

Effects of repeated YKS administration on neurotransmitter levels in the PVN. (A) After administration of YKS for 14 days, PVN dialysates were collected during a 60-minute RS exposure on day 14. ○, vehicle + RS (n = 4); ●, YKS + RS (n = 6). *Significantly different (P < .05) from 0 min in each group; #significantly different (P < .05) from the vehicle + RS group. (B) Diagrammatic representation of rat brain frontal plates from Paxinos and Watson³³, showing the placement of the microdialysis probe. (C) Representative ion chromatograms for standard neurotransmitters and their internal standards from LC-ITMSⁿ analysis. Abbreviations are the same as in Figure 5.

Discussion

Stress exposure causes sympathetic activation such as hypertension and tachycardia. Stress-induced increases in plasma catecholamine levels trigger these sympathetic responses. Previous studies clearly revealed that acute RS exposure greatly stimulates release and/or secretion of catecholamines.^9,34,35 Consistent with these previous studies, we also found that acute RS caused a large increase in plasma levels of both noradrenaline and adrenaline in vehicle-treated rats, as shown in Figure 2. In the present study, to determine if YKS treatment can affect stress-induced sympathetic activation, we examined the effects of YKS treatment on RS-induced catecholamine responses and prostanoid production in the PVN.

Several lines of evidence have demonstrated that repeated administration of YKS is more effective than a single administration in ameliorating anxiety-like behavior^18,20,25 and aggressive behavior.²⁴ However, several studies have suggested that single and repeated administration of YKS have different effects. Yamaguchi et al²⁰ reported that a single administration of YKS suppresses innate fear as measured by elevated plus maze test, whereas repeated administration shows anxiolytic effects for both innate fear and conditioned fear in a contextual fear conditioning test. Other studies indicated that single administration of YKS affects only social abnormalities but repeated administration ameliorates aggression in addition to sociality,^24,26 suggesting that YKS might have an acute effect on social behavior and a chronic effect on aggressive behavior. Taken together, most previous findings suggested the benefits of repeated YKS treatment for abnormal behaviors and the possibility that a single treatment may also be effective in some cases. Therefore, in our first experiment, we tried to reveal whether a single administration of YKS exerts effects on stress-induced sympathetic activation. However, our results showed that a single administration of YKS did not affect the RS-induced elevation of either noradrenaline or adrenaline levels. Therefore, we next aimed to examine the effects of chronic YKS treatment on RS-induced sympathetic activation and changes in neurotransmitter levels in the PVN.

It has been reported that YKS added to food at a dose of 300 mg/kg for 10 days has no influence on arterial blood pressure during cerebral ischemia and reperfusion in mice.³⁶ However, the effects of YKS treatment on sympathetic activation during stress exposure remain unknown. In this study, we examined the effects of repeated YKS administration on acute RS-induced elevation of plasma catecholamine levels. Our results showed that repeated administration of YKS significantly suppressed the RS-induced increase in adrenaline but not noradrenaline plasma levels. In general, plasma noradrenaline levels reflect noradrenaline spillover from sympathetic nerve terminals to plasma (and/or noradrenaline secreted from the adrenal medulla), whereas plasma adrenaline is only secreted from the adrenal medulla.^37,38 These differences suggest that plasma noradrenaline acts mainly in a target organ-specific manner, whereas plasma adrenaline acts systemically. Based on previous findings and our current results, the combined data raise the possibility that repeated administration of YKS has a selective effect on sympathetic responses induced by stress exposure and that YKS can suppress systemic sympathetic responses to stress via suppression of adrenaline secretion. Although the detailed mechanisms underlying YKS-mediated suppression of catecholamine levels remain unclear, one possible mechanism may involve neuroinflammatory mediators. We previously reported that central inhibition of inducible nitric oxide synthase (iNOS) suppresses CRF- and RS-induced elevation of plasma catecholamine levels and activation of presympathetic PVN neurons,^8,39 and that iNOS is involved in the interleukin (IL)-1β-induced elevation of plasma noradrenaline levels.⁴⁰ A previous in vitro study showed that YKS treatment suppressed the expression of iNOS and IL-1β mRNA and protein in lipopolysaccharide-stimulated BV2 cells.⁴¹ These pathways, including iNOS and IL-1β, might also be involved in the suppressive effects of YKS on plasma catecholamine elevation.

It is well-known that the PVN is the major integrative center for sympathetic function and stress responses in the brain.² The PVN contains presympathetic neurons which directly or indirectly project to sympathetic preganglionic neurons in the spinal cord.^42,43 We have previously reported that prostanoids in the brain, especially in the PVN, are involved in CRF- and RS-induced elevation of plasma catecholamine levels.^5,6,9 In addition, it has also been shown that inhibition of cyclooxygenase (COX), which is the rate-limiting enzyme in the synthesis of prostanoids, results in CRF- and RS-induced elevation of both noradrenaline and adrenaline levels.^5,8 Therefore, in this study, we examined whether repeated YKS administration can affect prostanoid production in the PVN during RS exposure, as prostanoids are important factors in activating sympathetic function. We found that acute RS significantly increased both PGE₂ and TxB₂ (a metabolite of TxA₂) levels, which peaked in the 40-min fraction, in PVN microdialysates. These results are generally consistent with a previous report using RS-exposed rats.⁹ Furthermore, in the present study, our results showed that YKS administration suppressed the elevation of both PGE₂ and TxB₂ levels in the PVN. It has also been reported that YKS decreased substance P-induced COX-2 expression in U373 MG glioblastoma astrocytoma cells.⁴⁴ Consistent with this, we previously found that the inhibition of COX-1 and COX-2 suppresses the RS-induced elevation of plasma catecholamine levels and neuronal activation of presympathetic PVN neurons.⁸ Taken together, it is highly possible that YKS induces the downregulation of COX(s) in the PVN and then decreases prostanoid production in the PVN, leading to suppression of the RS-induced elevation of plasma catecholamine levels.

Finally, we examined the effects of YKS on stress-dependent changes in neurotransmitter release in the PVN. In the present study, we analyzed 4 neurotransmitters (5-HT, GABA, ACh, and histamine) in PVN dialysates from rats that were repeatedly administered YKS for 14 days. Our results showed that RS exposure significantly increased 5-HT, GABA, and ACh, but not histamine, in the PVN, and that repeated administration of YKS suppressed the RS-induced increase in these neurotransmitters. It has been reported that the activities of 5-HT,⁴⁵ GABA (via GABA_B, but not GABA_A, receptors),^46,47 and ACh⁴⁸ in the PVN are involved in sympathetic activation. Therefore, it is possible that the YKS-induced decrease in these transmitter levels in the PVN shown in our study might be related to YKS-dependent suppression of sympathetic activation during stress exposure. Several previous studies have revealed that repeated YKS administration affects neurotransmitter levels in various brain regions. For example, dietary zinc deficiency increases the concentration of GABA, glutamate, and dopamine in brain homogenates of socially isolated mice, and YKS treatment restores the transmitters to normal levels.²⁸ In contrast, other studies have revealed that decreases in neurotransmitters in the brain, that is, ischemia-induced reduction of ACh release in the dorsal hippocampus²⁷ and age-dependent reductions in 5-HT concentration in the prefrontal cortex,³¹ are improved by YKS treatment in rodents. Although the cause of this discrepancy remains unknown, there is a possibility that YKS can normalize neurotransmitter levels—whether decreasing or increasing. The relationship between the YKS-induced normalization of neurotransmitter levels and the YKS-induced suppression of catecholamine levels during RS exposure shown in our study remains unclear at this time. These details need to be further investigated in future studies.

Conclusions

In this study, we investigated the effects of YKS on stress-induced sympathetic activation in rats. Our results showed that repeated administration of YKS suppressed the RS-induced elevation of plasma adrenaline, but not noradrenaline, levels. Moreover, the YKS administration also suppressed the elevation of both PGE₂ and TxB₂ levels in the PVN, which is the major integrative center for sympathetic regulation. We also found that YKS administration suppressed the RS-induced increase in 5-HT, GABA, and ACh, but not histamine, in the PVN. Our results suggest that YKS can ameliorate stress-induced sympathetic activation via inhibition of stress responses in the brain.

Materials and Methods

Animals

Male Wistar rats weighing ∼ 380 g were maintained in an air-conditioned room at 22 °C to 24 °C under a constant day-night rhythm for more than 3 weeks with food and water provided ad libitum. All experiments were conducted in compliance with the guiding principles for the care and use of laboratory animals approved by Aichi Medical University (Nos. 2019-1 and 2020-39).

Experimental Design

We first examined whether a single administration of YKS can affect the stress-induced elevation of plasma catecholamine (noradrenaline and adrenaline) levels (n = 18). In the next experiments, to determine the effects of repeated administration of YKS on stress-induced activation of the sympathetic nervous system, we examined plasma catecholamine levels and PVN prostanoid levels (PGE₂ and TxB₂) during stress exposure in YKS-administered rats (n = 19). In addition to the effects of YKS on stress-induced sympathetic activation, the effects of YKS on neurotransmitter levels in the PVN during stress exposure (n = 10) were also analyzed. In the 2 later experiments, all rats were administered YKS or vehicle daily for 14 days, then were exposed to RS for 60 min on day 14 (Figure 1). In parallel, PVN dialysate was collected before and during exposure to RS.

Drug Administration

A dried extract powder of YKS (Lot No. 2170054020) was kindly provided by Tsumura & Co. (Tokyo, Japan). YKS was prepared by Tsumura & Co.: all 7 herbs were extracted with purified water (95 °C, 1 h), and the extraction liquid was separated from the insoluble waste and concentrated by drying under diminished pressure. Spray drying was used to produce an extract powder, and the yield of the extract was about 15.9%.⁴⁹

YKS was dissolved in distilled water (1000 mg/10 mL). The dose of YKS (1000 mg/10 mL/kg, p.o.) was determined based on previous studies showing ameliorative effects on stress-induced behavioral abnormalities and corticosterone elevation.^17,20,23,24 It has been reported that repeated administration, but not single administration, of YKS for 14 days had ameliorative effects on anxiety and emotional abnormalities.^18,25 In our first experiment, a single administration of YKS 4 h prior to stress exposure did not affect the stress-induced elevation of plasma catecholamine levels (Figure 2). We thus administered YKS daily for 14 days in the subsequent experiments. Four hours after the last administration on day 14, all rats were subjected to dialysis experiments.

Restraint Stress

Exposure to RS was performed according to our previous reports.^8,9 All rats were restrained by taping their body trunk and 4 limbs to a metal mesh for 60 min.

Microdialysis

Microdialysis experiments were performed according to our previously published methods.^6,9 On day 9 (5 days before the dialysis experiments), rats were anesthetized intravenously with a mixture of medetomidine, midazolam, and butorphanol (0.75, 4.0, and 5.0 mg/kg, respectively), then a guide cannula (Eicom, Kyoto, Japan) was implanted for a microdialysis probe.^6,9 After the last administration of YKS on day 14, a microdialysis probe (Eicom, Kyoto, Japan) was inserted into the right side of the PVN.^6,9 After stabilization for 4 h, dialysis samples for the pre-RS time point were collected for 60 min prior to the stress exposure; rats were then subjected to RS for 60 min (Figure 1).

Measurement of Plasma Catecholamines

Catecholamine levels in plasma samples were assayed according to our previously published methods^3,5,9 by high-performance liquid chromatography (HPLC) with electrochemical detection (HTEC-510, Eicom, Kyoto, Japan).

Measurement of PGE₂ and TxB₂ in PVN Microdialysates

PGE₂ and TxB₂ (a metabolite of TxA₂) in PVN microdialysates were assayed according to our previous reports^9,50 by liquid chromatography-ion trap tandem mass spectrometry (LC-ITMSⁿ) analysis. To measure prostanoid concentrations in the dialysates, the peak area ratio relative to an internal standard was calculated and determined from the corresponding calibration curve.

Measurement of Neurotransmitters in PVN Microdialysates

Neurotransmitters (5-HT, GABA, Ach, and histamine) in PVN microdialysates were analyzed according to our previously published methods^47,51 by LC-ITMSⁿ analysis. To measure neurotransmitter concentrations in the dialysates, the peak area ratio relative to an internal standard was calculated and determined from the corresponding calibration curve.

Data Analysis and Statistics

Data are expressed as the mean ± SEM Plasma catecholamine levels are displayed as the net change above the respective basal values, and data from the microdialysates (prostanoids and neurotransmitters) are shown as a percentage of the respective basal values. The data were analyzed by a one-way ANOVA followed by a post hoc analysis with the Bonferroni method (Figures 2 and 3) and by a two-way ANOVA for the main effects of treatment (vehicle or YKS) and time (0, 20, 40, or 60 min from the start of RS) and their interaction with SPSS v25.0 (IBM, New York, NY, USA) followed by a post hoc analysis with the Bonferroni method (Figures 4 to 6). P values < .05 are defined as being statistically significant.

Footnotes

Abbreviations

Acknowledgments

We thank Natsumi Kodama and Makoto Naruse (Division of Advanced Research Promotion, Institute of Comprehensive Medical Research, Aichi Medical University) for expert assistance in the LC-ITMSⁿ experiment, and thank also Atsushi Iida, Shotaro Takemoto, Koshiro Tanamoto, Momoko Higuchi, Marimo Yonesu, and Mayuko Watanabe (School of Medicine and Aichi Medical School) for assistance in the preliminary experiments. We thank Tsumura & Co. (Tokyo, Japan) for generously providing Yokukansan.

Authors Contributions

Naoko Yamaguchi: conceptualization, methodology, formal analysis, investigation, writing–original draft, writing–review and editing, funding acquisition. Kenta Maruyama: formal analysis, writing–review and editing. Shoshiro Okada: writing–review and editing, funding acquisition.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical Approval

This study was approved by Aichi Medical University (Nos. 2019-1 and 2020-39).

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by JSPS KAKENHI Grant Number 20K07982 (to N.Y.) and the Research Foundation for Oriental Medicine (to S.O.).

Informed Consent

There are no human subjects in this article and informed consent is not applicable.

ORCID iD

Naoko Yamaguchi

Statement of Human and Animal Rights

All procedures in this study were conducted in accordance with the guiding principles for the care and use of laboratory animals approved by Aichi Medical University (Nos. 2019-1 and 2020-39).

Supporting Information

The data presented in this study are included in this article. Further inquiries can be directed to the corresponding author.

References

Pacak

Palkovits

Kopin

Goldstein

. Stress-induced norepinephrine release in the hypothalamic paraventricular nucleus and pituitary-adrenocortical and sympathoadrenal activity: in vivo microdialysis studies. Front Neuroendocrinol. 1995;16(2):89-150. doi:10.1006/frne.1995.1004

Swanson

Sawchenko

. Paraventricular nucleus: a site for the integration of neuroendocrine and autonomic mechanisms. Neuroendocrinology. 1980;31(6):410-417. doi:10.1159/000123111

Okada

Yamaguchi

. Possible role of adrenoceptors in the hypothalamic paraventricular nucleus in corticotropin-releasing factor-induced sympatho-adrenomedullary outflow in rats. Auton Neurosci. 2017;203:74-80. doi: 10.1016/j.autneu.2017.01.008

Ross

Ruggiero

Park

, et al Tonic vasomotor control by the rostral ventrolateral medulla: effect of electrical or chemical stimulation of the area containing C1 adrenaline neurons on arterial pressure, heart rate, and plasma catecholamines and vasopressin. J Neurosci. 1984;4(2):474-494. doi:10.1523/JNEUROSCI.04-02-00474.1984

Okada

Murakami

Yokotani

. Role of brain thromboxane A₂ in the release of noradrenaline and adrenaline from adrenal medulla in rats. Eur J Pharmacol. 2003;467(1-3):125-131. doi:10.1016/s0014-2999(03)01629-7

Yamaguchi

Mimura

Okada

. Prostaglandin E₂ receptor EP₃ subtype in the paraventricular hypothalamic nucleus mediates corticotropin-releasing factor-induced elevation of plasma noradrenaline levels in rats. Eur J Pharmacol. 2019;863:172693. doi:10.1016/j.ejphar.2019.172693

Tachi

Yamaguchi

Okada

. Thromboxane A₂ in the paraventricular hypothalamic nucleus mediates glucoprivation-induced adrenomedullary outflow. Eur J Pharmacol. 2020;875:173034. doi:10.1016/j.ejphar.2020.173034

Yamaguchi

Ogawa

Okada

. Cyclooxygenase and nitric oxide synthase in the presympathetic neurons in the paraventricular hypothalamic nucleus are involved in restraint stress-induced sympathetic activation in rats. Neuroscience. 2010;170(3):773-781. doi:10.1016/j.neuroscience.2010.07.051

Yamaguchi

Kakinuma

Yakura

Naito

Okada

. Glucose infusion suppresses acute restraint stress-induced peripheral and central sympathetic responses in rats. Auton Neurosci. 2022;239:102957. doi:10.1016/j.autneu.2022.102957

10.

Ikarashi

Mizoguchi

. Neuropharmacological efficacy of the traditional Japanese Kampo medicine Yokukansan and its active ingredients. Pharmacol Ther. 2016;166:84-95. doi:10.1016/j.pharmthera.2016.06.018

11.

Iwasaki

Satoh-Nakagawa

Maruyama

, et al. A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. J Clin Psychiatry. 2005;66(2):248-252. doi:10.4088/jcp.v66n0214

12.

Matsuda

Kishi

Shibayama

Iwata

. Yokukansan in the treatment of behavioral and psychological symptoms of dementia: a systematic review and meta-analysis of randomized controlled trials. Hum Psychopharmacol. 2013;28(1):80-86. doi:10.1002/hup.2286

13.

Mizukami

Asada

Kinoshita

, et al. A randomized cross-over study of a traditional Japanese medicine (Kampo), Yokukansan, in the treatment of the behavioural and psychological symptoms of dementia. Int J Neuropsychopharmacol. 2009;12(2):191-199. doi:10.1017/S146114570800970X

14.

Mizoguchi

Ikarashi

. Multiple psychopharmacological effects of the traditional Japanese Kampo medicine Yokukansan, and the brain regions it affects. Front Pharmacol. 2017;8:149. doi:10.3389/fphar.2017.00149

15.

Fujiwara

Takayama

Iwasaki

, et al. Yokukansan, a traditional Japanese medicine, ameliorates memory disturbance and abnormal social interaction with anti-aggregation effect of cerebral amyloid β proteins in amyloid precursor protein transgenic mice. Neuroscience. 2011;180:305-313. doi:10.1016/j.neuroscience.2011.01.064

16.

Ikarashi

Iizuka

Imamura

, et al. Effects of Yokukansan, a traditional Japanese medicine, on memory disturbance and behavioral and psychological symptoms of dementia in thiamine-deficient rats. Biol Pharm Bull. 2009;32(10):1701-1709. doi:10.1248/bpb.32.1701

17.

Tabuchi

Mizuno

Mizoguchi

Hattori

Kase

. Yokukansan and yokukansankachimpihange ameliorate aggressive behaviors in rats with cholinergic degeneration in the nucleus basalis of Meynert. Front Pharmacol. 2017;8:235. doi:10.3389/fphar.2017.00235

18.

Shoji

Mizoguchi

. Brain region-specific reduction in c-Fos expression associated with an anxiolytic effect of Yokukansan in rats. J Ethnopharmacol. 2013;149(1):93-102. doi:10.1016/j.jep.2013.06.005

19.

Tamano

Morioka

Iwaki

Suzuki

Sato

Takeda

. Yokukansan, a herbal medicine in Japan, buffers social crowding stress via ameliorating glucocorticoid secretion response to vasopressin. Biol Pharm Bull. 2018;41(6):920-924. doi:10.1248/bpb.b18-00052

20.

Yamaguchi

Tsujimatsu

Kumamoto

, et al. Anxiolytic effects of Yokukansan, a traditional Japanese medicine, via serotonin 5-HT_1A receptors on anxiety-related behaviors in rats experienced aversive stress. J Ethnopharmacol. 2012;143(2):533-539. doi:10.1016/j.jep.2012.07.007

21.

Kanada

Katayama

Ikemoto

, et al. Inhibitory effect of the Kampo medicinal formula Yokukansan on acute stress-induced defecation in rats. Neuropsychiatr Dis Treat. 2018;14:937-944. doi:10.2147/NDT.S156795

22.

Katahira

Sunagawa

Watanabe

, et al. Antistress effects of Kampo medicine “Yokukansan” via regulation of orexin secretion. Neuropsychiatr Dis Treat. 2017;13:863-872. doi:10.2147/NDT.S129418

23.

Shimizu

Tanaka

Takeda

Tohyama

Miyata

. The Kampo medicine Yokukansan decreases microRNA-18 expression and recovers glucocorticoid receptors protein expression in the hypothalamus of stressed mice. BioMed Res Int. 2015;2015:797280. doi:10.1155/2015/797280

24.

Nishi

Yamaguchi

Sekiguchi

, et al. Geissoschizine methyl ether, an alkaloid in Uncaria hook, is a potent serotonin_1A receptor agonist and candidate for amelioration of aggressiveness and sociality by Yokukansan. Neuroscience. 2012;207:124-136. doi:10.1016/j.neuroscience.2012.01.037

25.

Tsuji

Takeuchi

Miyagawa

, et al. Yokukansan, a traditional Japanese herbal medicine, alleviates the emotional abnormality induced by maladaptation to stress in mice. Phytomedicine. 2014;21(3):363-371. doi:10.1016/j.phymed.2013.08.025

26.

Kanno

Sekiguchi

Yamaguchi

, et al. Effect of Yokukansan, a traditional Japanese medicine, on social and aggressive behaviour of para-chloroamphetamine-injected rats. J Pharm Pharmacol. 2009;61(9):1249-1256. doi: 10.1211/jpp/61.09.0016

27.

Nogami-Hara

Nagao

Takasaki

, et al. The Japanese Angelica acutiloba root and Yokukansan increase hippocampal acetylcholine level, prevent apoptosis and improve memory in a rat model of repeated cerebral ischemia. J Ethnopharmacol. 2018;214:190-196. doi:10.1016/j.jep.2017.12.025

28.

Tamano

Kan

Oku

Takeda

. Ameliorative effect of Yokukansan on social isolation-induced aggressive behavior of zinc-deficient young mice. Brain Res Bull. 2010;83(6):351-355. doi:10.1016/j.brainresbull.2010.08.013

29.

Egashira

Nogami

Iwasaki

, et al. Yokukansan enhances pentobarbital-induced sleep in socially isolated mice: possible involvement of GABA_A-benzodiazepine receptor complex. J Pharmacol Sci. 2011;116(3):316-320.

30.

Takeda

Iwaki

Ide

Tamano

Oku

. Therapeutic effect of Yokukansan on social isolation-induced aggressive behavior of zinc-deficient and pair-fed mice. Brain Res Bull. 2012;87(6):551-555. doi:10.1016/j.brainresbull.2012.02.003

31.

Mizoguchi

Tanaka

Tabira

. Anxiolytic effect of a herbal medicine, Yokukansan, in aged rats: involvement of serotonergic and dopaminergic transmissions in the prefrontal cortex. J Ethnopharmacol. 2010;127(1):70-76. doi:10.1016/j.jep.2009.09.048

32.

Uchida

Takasaki

Sakata

, et al. Cholinergic involvement and synaptic dynamin 1 expression in Yokukansan-mediated improvement of spatial memory in a rat model of early Alzheimer’s disease. Phytother Res. 2013;27(7):966-972. doi:10.1002/ptr.4818

33.

Paxinos

Watson

. The Rat Brain in Stereotaxic Coordinates. 5th edition. Academic Press; 2005.

34.

Kvetnansky

Sun

Lake

Thoa

Torda

Kopin

. Effect of handling and forced immobilization on rat plasma levels of epinephrine, norepinephrine, and dopamine-β-hydroxylase. Endocrinology. 1978;103(5):1868-1874. doi:10.1210/endo-103-5-1868

35.

Pajovic

Pejic

Stojiljkovic

Gavrilovic

Dronjak

Kanazir

. Alterations in hippocampal antioxidant enzyme activities and sympatho-adrenomedullary system of rats in response to different stress models. Physiol Res. 2006;55(4):453-460. doi:10.33549/physiolres.930807

36.

Kitabayashi

Ito

Kawasaki

, et al. Effect of Yokukansan on nitric oxide production and hydroxyl radical metabolism during cerebral ischemia and reperfusion in mice. J Stroke Cerebrovasc Dis. 2019;28(5):1151-1159. doi:10.1016/j.jstrokecerebrovasdis.2018.12.047

37.

Esler

Jennings

Lambert

Meredith

Horne

Eisenhofer

. Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. Physiol Rev. 1990;70(4):963-985. doi:10.1152/physrev.1990.70.4.963

38.

Hasking

Jennings

Burton

Korner

. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence for increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73(4):615-621. doi:10.1161/01.cir.73.4.615

39.

Okada

Yokotani

. Inducible nitric oxide synthase is involved in corticotropin-releasing hormone-mediated central sympatho-adrenal outflow in rats. Eur J Pharmacol. 2003;477(2):95-100. doi:10.1016/j.ejphar.2003.08.009

40.

Murakami

Okada

Yokotani

. Brain inducible nitric oxide synthase is involved in interleukin-1β-induced activation of the central sympathetic outflow in rats. Eur J Pharmacol. 2002;455(1):73-78. doi:10.1016/s0014-2999(02)02580-3

41.

Nomura

Bando

You

Tanaka

Yoshida

. Yokukansan reduces cuprizone-induced demyelination in the corpus callosum through anti-inflammatory effects on microglia. Neurochem Res. 2017;42(12):3525-3536. doi:10.1007/s11064-017-2400-z

42.

Appel

Elde

. The intermediolateral cell column of the thoracic spinal cord is comprised of target-specific subnuclei: evidence from retrograde transport studies and immunohistochemistry. J Neurosci. 1988;8(5):1767-1775. doi:10.1523/JNEUROSCI.08-05-01767.1988

43.

Pyner

Coote

. Identification of branching paraventricular neurons of the hypothalamus that project to the rostroventrolateral medulla and spinal cord. Neuroscience. 2000;100(3):549-556. doi:10.1016/s0306-4522(00)00283-9

44.

Yamaguchi

Yamazaki

Kumakura

, et al. Yokukansan, a Japanese herbal medicine, suppresses substance P-induced production of interleukin-6 and interleukin-8 by human U373 MG glioblastoma astrocytoma cells. Endocr Metab Immune Disord Drug Targets. 2020;20(7):1073-1080. doi:10.2174/1871530320666200131103733

45.

Sakaguchi

Bray

. Effect of norepinephrine, serotonin and tryptophan on the firing rate of sympathetic nerves. Brain Res. 1989;492(1-2):271-280. doi:10.1016/0006-8993(89)90910-4

46.

Nonogaki

Mizuno

Sakamoto

Iguchi

. Effects of central GABA receptors activation on catecholamine secretion in rats. Life Sci. 1994;55(12):PL239-PL243. doi:10.1016/0024-3205(94)00544-3

47.

Yamaguchi

Mimura

Okada

. GABA_B receptors in the hypothalamic paraventricular nucleus mediate β-adrenoceptor-induced elevations of plasma noradrenaline in rats. Eur J Pharmacol. 2019;848:88-95. doi: 10.1016/j.ejphar.2019.01.029

48.

Qadri

Waldmann

Wolf

Höhle

Rascher

Unger

. Differential contribution of angiotensinergic and cholinergic receptors in the hypothalamic paraventricular nucleus to osmotically induced AVP release. J Pharmacol Exp Ther. 1998;285(3):1012-1018.

49.

Terawaki

Ikarashi

Sekiguchi

Nakai

Kase

. Partial agonistic effect of Yokukansan on human recombinant serotonin 1A receptors expressed in the membranes of Chinese hamster ovary cells. J Ethnopharmacol. 2010;127(2):306-312. doi:10.1016/j.jep.2009.11.003

50.

Tachi

Kondo

Fukayama

Yoshikawa

Matsuura

Okada

. Mass spectrometric determination of prostanoids in rat hypothalamic paraventricular nucleus microdialysates. Auton Neurosci. 2014;181:49-54. doi: 10.1016/j.autneu.2013.12.013

51.

Kondo

Tachi

Gosho

Fukayama

Yoshikawa

Okada

. Changes in hypothalamic neurotransmitter and prostanoid levels in response to NMDA, CRF, and GLP-1 stimulation. Anal Bioanal Chem. 2015;407(18):5261-5272. doi: 10.1007/s00216-015-8496-6

Yokukansan,a Traditional Japanese Medicine,Suppresses Stress-Induced Sympathetic Activation via Central Responses in Rats

Abstract

Keywords

Introduction

Results

Effects of a Single Administration of YKS on RS-Induced Elevation of Plasma Catecholamine Levels

Effects of Repeated Administration of YKS on Body Weight

Effects of Repeated Administration of YKS on RS-Induced Elevation of Plasma Catecholamine Levels

Effects of Repeated YKS Administration on RS-Induced Elevation of PGE2 and TxB2 Levels in the PVN

Effects of Repeated YKS Administration on Neurotransmitter Levels in the PVN

Discussion

Conclusions

Materials and Methods

Animals

Experimental Design

Drug Administration

Restraint Stress

Microdialysis

Measurement of Plasma Catecholamines

Measurement of PGE2 and TxB2 in PVN Microdialysates

Measurement of Neurotransmitters in PVN Microdialysates

Data Analysis and Statistics

Footnotes

Abbreviations

Acknowledgments

Authors Contributions

Declaration of Conflicting Interests

Ethical Approval

Funding

Informed Consent

ORCID iD

Statement of Human and Animal Rights

Supporting Information

References

Effects of Repeated YKS Administration on RS-Induced Elevation of PGE₂ and TxB₂ Levels in the PVN

Measurement of PGE₂ and TxB₂ in PVN Microdialysates